Obsidian Therapeutics, Inc. OBX

OBX Company Overview

Obsidian Therapeutics, Inc. is a biotechnology company focused on developing engineered cell and gene therapies for oncology and other serious diseases. The company operates within the biopharmaceutical and immunotherapy industries, with a primary emphasis on controllable gene expression technologies designed to improve the safety, efficacy, and precision of therapeutic cell therapies. Obsidian’s platform centers on regulated protein expression systems that allow clinicians to modulate therapeutic activity after administration, particularly in engineered T-cell therapies and cytokine delivery applications.

The company was founded in 2015 and emerged from research involving synthetic biology and cellular engineering technologies developed by academic and industry scientists. Obsidian has positioned itself within the competitive immuno-oncology sector by focusing on “cytokine armoring” and controlled gene expression approaches intended to address limitations associated with conventional CAR-T and tumor-infiltrating lymphocyte therapies. Its strategy has emphasized programmable cell therapies that may improve therapeutic durability while reducing toxicity risks.